Comparative Pharmacology
Head-to-head clinical analysis: TRIAZOLAM versus VALIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAZOLAM versus VALIUM.
TRIAZOLAM vs VALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triazolam is a benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, potentiating the inhibitory effects of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
0.125-0.25 mg orally once daily at bedtime; maximum 0.5 mg/day.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
None Documented
None Documented
1.5-5.5 hours (mean 2-4 hours) in healthy adults; prolonged in hepatic cirrhosis and elderly.
Clinical Note
moderateTriazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone propionate."
Clinical Note
moderateTriazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Triazolam."
Clinical Note
moderateTriazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Triazolam."
Clinical Note
moderateTriazolam + Cyclosporine
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Primarily renal: approximately 80% as metabolites, less than 2% unchanged; biliary/fecal: minor (about 8-10%).
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Triazolam."